[go: up one dir, main page]

AU2001288598A1 - A novel cationic lipopolymer as biocompatible gene delivery agent - Google Patents

A novel cationic lipopolymer as biocompatible gene delivery agent

Info

Publication number
AU2001288598A1
AU2001288598A1 AU2001288598A AU8859801A AU2001288598A1 AU 2001288598 A1 AU2001288598 A1 AU 2001288598A1 AU 2001288598 A AU2001288598 A AU 2001288598A AU 8859801 A AU8859801 A AU 8859801A AU 2001288598 A1 AU2001288598 A1 AU 2001288598A1
Authority
AU
Australia
Prior art keywords
gene delivery
delivery agent
cationic lipopolymer
novel cationic
pei
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001288598A
Inventor
Darin Y. Furgeson
Sang-Oh Han
Ram I. Mahato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Expression Genetics Inc
Original Assignee
Expression Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Expression Genetics Inc filed Critical Expression Genetics Inc
Publication of AU2001288598A1 publication Critical patent/AU2001288598A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Saccharide Compounds (AREA)

Abstract

A biodegradable non-toxic cationic lipopolymer comprising a branched polyethylenimine (PEI), a lipid anchor, biocompatible hydrophilic polymer spacer, and a biodegradable linker which covalently links the branched PEI, the spacer and the cholesterol derived lipid anchor. The cationic lipopolymers in the present invention can be used in drug delivery and are especially useful for delivery of a nucleic acid or any anionic bioactive agent to various organs and tissues after local or systemic administration.
AU2001288598A 2000-09-14 2001-08-31 A novel cationic lipopolymer as biocompatible gene delivery agent Abandoned AU2001288598A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/662,511 US6696038B1 (en) 2000-09-14 2000-09-14 Cationic lipopolymer as biocompatible gene delivery agent
US09/662,511 2000-09-14
PCT/US2001/027181 WO2002022174A1 (en) 2000-09-14 2001-08-31 A novel cationic lipopolymer as biocompatible gene delivery agent

Publications (1)

Publication Number Publication Date
AU2001288598A1 true AU2001288598A1 (en) 2002-03-26

Family

ID=24658024

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001288598A Abandoned AU2001288598A1 (en) 2000-09-14 2001-08-31 A novel cationic lipopolymer as biocompatible gene delivery agent

Country Status (9)

Country Link
US (2) US6696038B1 (en)
EP (1) EP1320386B1 (en)
JP (1) JP2004522809A (en)
AT (1) ATE502652T1 (en)
AU (1) AU2001288598A1 (en)
CA (1) CA2420495C (en)
DE (1) DE60144281D1 (en)
ES (1) ES2364006T3 (en)
WO (1) WO2002022174A1 (en)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070173465A9 (en) * 1995-10-11 2007-07-26 Monahan Sean D Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
CA2416289C (en) * 2000-07-21 2012-12-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US20040142474A1 (en) * 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
DE10065710A1 (en) * 2000-12-29 2002-07-04 Bayer Ag Medicament containing a polyamine as an active substance
US6875611B2 (en) * 2001-07-03 2005-04-05 University Of Utah Research Foundation Soluble steroidal peptides for nucleic acid delivery
CA2456977C (en) * 2001-08-16 2011-06-07 The Trustees Of The University Of Pennsylvania Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
US20030215395A1 (en) * 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
EA200401565A1 (en) * 2002-05-24 2005-04-28 Неофарм, Инк. METHOD FOR OBTAINING CARDIOLYPINE OR ANALOGUE OF CARDIOLIPINE (OPTIONS), METHOD FOR OBTAINING LIPOSOME AND COMPOSITION OF CARDIOLIPINE FOR TREATING DISEASES (OPTIONS)
CA2486967A1 (en) * 2002-05-24 2003-12-04 Neopharm, Inc. Cardiolipin compositions their methods of preparation and use
GB0221942D0 (en) * 2002-09-20 2002-10-30 Univ Strathclyde Drug delivery
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20040138154A1 (en) 2003-01-13 2004-07-15 Lei Yu Solid surface for biomolecule delivery and high-throughput assay
US6878374B2 (en) * 2003-02-25 2005-04-12 Nitto Denko Corporation Biodegradable polyacetals
US7883720B2 (en) * 2003-07-09 2011-02-08 Wisconsin Alumni Research Foundation Charge-dynamic polymers and delivery of anionic compounds
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US7163677B2 (en) 2003-10-24 2007-01-16 Nitto Denko Corporation Cationic polymers having degradable crosslinks
EP2418281B1 (en) 2003-10-24 2016-06-01 Gencia Corporation Methods and compositions for delivering polynucleotides
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
LT2985039T (en) 2004-03-03 2018-11-12 Revance Therapeutics, Inc. Topical application and transdermal delivery of botulinum toxins
CN101083907B (en) * 2004-03-03 2012-10-10 雷文斯治疗公司 Compositions and methods for topical delivery of diagnostic and therapeutic agents
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8821859B2 (en) * 2004-05-19 2014-09-02 Agency For Science, Technology And Research Methods and articles for the delivery of therapeutic agents
FR2870741B1 (en) * 2004-05-25 2008-03-14 Coletica Sa HYDRATED LAMELLAR OR LIPOSOME PHASE CONTAINING A FATTY MONOAMINE OR A CATIONIC POLYMER PROMOTING INTERCELLULAR PENETRATION AND A COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING THE SAME.
CA2567741A1 (en) * 2004-05-25 2006-03-30 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
US20060293264A1 (en) * 2004-07-22 2006-12-28 Grandis Jennifer R STAT3 decoy oligonucleotides and uses therefor
JP5355890B2 (en) * 2004-09-09 2013-11-27 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム Liposomal composition of glucocorticoids and glucocorticoid derivatives
US7358223B2 (en) * 2004-10-04 2008-04-15 Nitto Denko Corporation Biodegradable cationic polymers
US8057821B2 (en) * 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
US20060105052A1 (en) * 2004-11-15 2006-05-18 Acar Havva Y Cationic nanoparticle having an inorganic core
US7964571B2 (en) * 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
PT2727583T (en) 2004-12-22 2021-12-27 Nitto Denko Corp Drug carrier and drug carrier kit for inhibiting fibrosis
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
US9180081B2 (en) 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
RU2007136617A (en) * 2005-03-03 2009-04-10 Риванс Терапьютикс, Инк. (Us) COMPOSITION AND METHOD FOR LOCAL USE AND TRANSMISSION OF OLIGOPEPTIDE
US8734851B2 (en) * 2005-04-29 2014-05-27 Wisconsin Alumni Research Foundation Localized delivery of nucleic acid by polyelectrolyte assemblies
JP2007043972A (en) * 2005-08-10 2007-02-22 Tokyo Institute Of Technology Apatite particles and production method thereof, gene-apatite particle complex and production method thereof, gene introduction method and gene introduction kit
AU2006315117A1 (en) * 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
US7700541B2 (en) * 2006-04-06 2010-04-20 Nitto Denko Corporation Biodegradable cationic polymers
US8067011B2 (en) * 2006-04-07 2011-11-29 Chimeros, Inc. Compositions and methods for treating B-cell malignancies
US8946200B2 (en) * 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
MX2009007068A (en) * 2006-12-29 2009-07-10 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat.
CA2672886C (en) * 2006-12-29 2015-02-10 Revance Therapeutics, Inc. Transport molecules using reverse sequence hiv-tat polypeptides
US8834918B2 (en) * 2007-01-22 2014-09-16 Wisconsin Alumni Research Foundation Modified multilayered film
TWI407971B (en) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
AU2008236566A1 (en) * 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
US20080312174A1 (en) * 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
CN102872447B (en) * 2007-07-26 2015-09-30 雷文斯治疗公司 Antimicrobial peptides, compositions and methods of use
US20090042825A1 (en) * 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
US8487079B2 (en) * 2007-08-08 2013-07-16 University of Pittsburgh—of the Commonwealth System of Higher Education Use of mitochondria-targeted electron scavengers as anti-inflammatory agents
JP2010539245A (en) 2007-09-14 2010-12-16 日東電工株式会社 Drug carrier
US20090105375A1 (en) * 2007-10-09 2009-04-23 Lynn David M Ultrathin Multilayered Films for Controlled Release of Anionic Reagents
US8404850B2 (en) * 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
US20100004315A1 (en) * 2008-03-14 2010-01-07 Gregory Slobodkin Biodegradable Cross-Linked Branched Poly(Alkylene Imines)
AU2015270888B2 (en) * 2008-05-28 2017-11-16 Wayne State University Method and composition for a protein transduction technology and its applications
US8722348B2 (en) 2008-05-28 2014-05-13 Wayne State University Method and composition for a protein transduction technology and its applications
US8324333B2 (en) 2008-06-05 2012-12-04 Wisconsin Alumni Research Foundation Anionic charge-dynamic polymers for release of cationic agents
US8722706B2 (en) * 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
TWI373368B (en) * 2008-11-11 2012-10-01 Univ Nat Chiao Tung Liposome and method for producing the same
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
WO2011084694A1 (en) 2009-12-17 2011-07-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Stabilized stat3 decoy oligonucleotides and uses therefor
US9028873B2 (en) * 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
JP5510808B2 (en) * 2010-03-10 2014-06-04 独立行政法人産業技術総合研究所 Nucleic acid introduction agent comprising organic nanotubes
CN101864078B (en) * 2010-06-01 2011-12-07 浙江大学 Polyethyleneimine-chitosan-octadecanoic acid grafting, preparation and application
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3590949B1 (en) 2010-10-01 2022-05-18 ModernaTX, Inc. Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
CA3131967A1 (en) * 2010-12-29 2012-07-05 F. Hoffman-La Roche Ag Small molecule conjugates for intracellular delivery of nucleic acids
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
AU2012305714A1 (en) 2011-09-09 2014-03-27 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS62993B1 (en) 2011-10-03 2022-03-31 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
GB201117538D0 (en) 2011-10-11 2011-11-23 Royal Veterinary College The Methods
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
KR102101210B1 (en) 2012-03-02 2020-04-16 고쿠리츠켄큐카이하츠호진 카가쿠기쥬츠신코키코 Method for constructing functional nucleic acid molecule, and nucleic acid combination to be used in said method
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
CN104411338A (en) 2012-04-02 2015-03-11 现代治疗公司 Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015513912A (en) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Modified polynucleotides for the production of proteins
US9109087B2 (en) * 2012-09-13 2015-08-18 International Business Machines Corporation Low molecular weight branched polyamines for delivery of biologically active materials
US8703197B2 (en) * 2012-09-13 2014-04-22 International Business Machines Corporation Branched polyamines for delivery of biologically active materials
PL2922554T3 (en) 2012-11-26 2022-06-20 Modernatx, Inc. Terminally modified rna
US20140200261A1 (en) 2013-01-17 2014-07-17 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
RS62529B1 (en) 2013-07-11 2021-11-30 Modernatx Inc Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CN105980401A (en) 2013-10-03 2016-09-28 现代治疗公司 Polynucleotides encoding low density lipoprotein receptor
ES2896021T3 (en) 2013-10-25 2022-02-23 Univ Wayne State Modified reprogramming protein for use in treating cancer
EP3082760A1 (en) 2013-12-19 2016-10-26 Novartis AG LEPTIN mRNA COMPOSITIONS AND FORMULATIONS
SG11201608798YA (en) 2014-04-23 2016-11-29 Modernatx Inc Nucleic acid vaccines
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
CN104224718B (en) * 2014-10-09 2017-07-11 辽宁中医药大学 A kind of multifunctional targeted vinorelbine liposome and preparation method thereof
JP2018513883A (en) * 2015-03-06 2018-05-31 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Macromolecular metformin and its use as a therapeutic agent and as a delivery vehicle
EP3350157B1 (en) 2015-09-17 2022-01-05 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
AU2016366978B2 (en) 2015-12-10 2022-07-28 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
JP7114465B2 (en) 2015-12-22 2022-08-08 モデルナティエックス インコーポレイテッド Compounds and compositions for intracellular delivery of drugs
WO2018071761A1 (en) 2016-10-13 2018-04-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Mitochondrially targeted parp inhibitor, and uses thereof
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP3596042B1 (en) 2017-03-15 2022-01-12 Modernatx, Inc. Crystal forms of amino lipids
SMT202300097T1 (en) 2017-03-15 2023-05-12 Modernatx Inc Compound and compositions for intracellular delivery of therapeutic agents
JP7332478B2 (en) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド Lipid nanoparticle formulation
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS, E.G. SUBcutaneously ADMINISTERED THERAPEUTIC PROTEINS
WO2018213731A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
EP3625345B1 (en) 2017-05-18 2023-05-24 ModernaTX, Inc. Modified messenger rna comprising functional rna elements
CN107184552B (en) * 2017-06-07 2021-03-30 东华大学 A kind of preparation method of galactosylated polyethyleneimine modified drug-loaded alcohol plastid
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
US20200268666A1 (en) 2017-06-14 2020-08-27 Modernatx, Inc. Polynucleotides encoding coagulation factor viii
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. Rna formulations
US11964057B2 (en) 2017-06-20 2024-04-23 Rjh Biosciences Inc. Transfection reagents for delivery of nucleic acids
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
EP3679140B1 (en) 2017-09-08 2022-11-16 MiNA Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
EP3714048B1 (en) 2017-11-22 2025-04-09 ModernaTX, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
WO2019104195A1 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
WO2019104160A2 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
WO2019136241A1 (en) 2018-01-05 2019-07-11 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
EP3775211B1 (en) 2018-04-12 2023-04-05 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
EP3796893A1 (en) 2018-05-23 2021-03-31 Modernatx, Inc. Delivery of dna
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
EP3833762A4 (en) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND THEIR USES
MA53545A (en) 2018-09-02 2021-07-14 Modernatx Inc POLYNUCLEOTIDES ENCODED FOR VERY LONG CHAIN ACYL-COA DEHYDROGENASE FOR THE TREATMENT OF VERY LONG CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY
WO2020056155A2 (en) 2018-09-13 2020-03-19 Modernatx, Inc. Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
MX2021003015A (en) 2018-09-13 2021-07-15 Modernatx Inc Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease.
AU2019339430A1 (en) 2018-09-14 2021-04-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide A1 for the treatment of Crigler-Najjar Syndrome
CN112996854B (en) 2018-09-19 2024-08-30 摩登纳特斯有限公司 High-purity PEG lipids and their uses
WO2020061367A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CA3113025A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
EP3852728B1 (en) 2018-09-20 2024-09-18 ModernaTX, Inc. Preparation of lipid nanoparticles and methods of administration thereof
US20220152225A1 (en) 2018-09-27 2022-05-19 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
WO2020208361A1 (en) 2019-04-12 2020-10-15 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
EP3965797A1 (en) 2019-05-08 2022-03-16 AstraZeneca AB Compositions for skin and wounds and methods of use thereof
CN112472805B (en) * 2019-07-26 2021-11-09 浙江大学 Boron-containing preparation with cell nucleus targeting property and preparation method and application thereof
BR112022004759A2 (en) 2019-09-19 2022-06-21 Modernatx Inc Branched tail lipid compositions and compounds for intracellular delivery of therapeutic agents
CN111154002B (en) * 2020-01-10 2022-11-22 上海海洋大学 Bifunctional peptide K14, gene carrier and drug-loading system
US20230172971A1 (en) * 2020-05-01 2023-06-08 The Board Of Regents Of The University Of Oklahoma Antibiotic and anti-inflammatory compositions and methods of use
WO2021247507A1 (en) 2020-06-01 2021-12-09 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
WO2022104131A1 (en) 2020-11-13 2022-05-19 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
US20240216288A1 (en) 2021-03-24 2024-07-04 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
US20240189449A1 (en) 2021-03-24 2024-06-13 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
TW202305133A (en) 2021-03-26 2023-02-01 英商米納治療有限公司 Tmem173 sarna compositions and methods of use
US20240384277A1 (en) 2021-06-15 2024-11-21 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
US20240376445A1 (en) 2021-06-22 2024-11-14 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
EP4408871A1 (en) 2021-10-01 2024-08-07 ModernaTX, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
WO2023183909A2 (en) 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
MA71619A (en) 2022-07-26 2025-05-30 Modernatx, Inc. MODIFIED POLYNUCLEOTIDES FOR TEMPORAL REGULATION OF EXPRESSION
TW202440929A (en) 2022-12-14 2024-10-16 加拿大商普羅維登斯治療控股公司 Compositions and methods for infectious diseases
WO2024134199A1 (en) 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
WO2024197033A1 (en) 2023-03-21 2024-09-26 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of heart failure
WO2024229321A1 (en) 2023-05-03 2024-11-07 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2025072482A1 (en) 2023-09-27 2025-04-03 Modernatx, Inc. Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
WO2025072615A1 (en) 2023-09-29 2025-04-03 Orbital Therapeutics, Inc. Improved methods of making rna by splinted ligation and compositions thereof
WO2025255199A1 (en) 2024-06-05 2025-12-11 Modernatx, Inc. Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4121982A (en) * 1978-02-03 1978-10-24 American Chemical & Refining Company Incorporated Gold alloy plating bath and method
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
JP3078107B2 (en) * 1992-04-07 2000-08-21 日本原子力研究所 Radioactive waste volume reduction method
US5393335A (en) * 1993-04-23 1995-02-28 Ppg Industries, Inc. Starch-oil sizing for glass fibers
FR2730637B1 (en) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa PHARMACEUTICAL COMPOSITION CONTAINING NUCLEIC ACIDS, AND USES THEREOF
AU5799996A (en) * 1995-05-26 1996-12-11 Cell Genesys, Inc. Delivery vehicles comprising stable lipid/nucleic acid compl exes
US5753262A (en) 1995-06-07 1998-05-19 Aronex Pharmaceuticals, Inc. Cationic lipid acid salt of 3beta N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof
AU739969B2 (en) * 1996-05-29 2001-10-25 Cell Genesys, Inc. Cationic polymer/lipid nucleic acid delivery vehicles
EP0979311A1 (en) * 1997-04-30 2000-02-16 Of The University Of Minnesota Regents $i(IN VIVO) USE OF RECOMBINAGENIC OLIGONUCLEOBASES TO CORRECT GENETIC LESIONS IN HEPATOCYTES
US5955415A (en) * 1997-08-04 1999-09-21 Lever Brothers Company, Division Of Conopco, Inc. Detergent compositions containing polyethyleneimines for enhanced peroxygen bleach stability
DE19743135A1 (en) * 1997-09-30 1999-04-01 Hoechst Marion Roussel De Gmbh Biologically compatible low molecular weight polyethyleneimines
TR200003441T2 (en) * 1998-05-20 2001-04-20 Expression Genetics, Inc. A polyethylene glyco-attached poly-1-lysine polymeric gene carrier targeting hepatocyte

Also Published As

Publication number Publication date
EP1320386A4 (en) 2005-01-26
DE60144281D1 (en) 2011-05-05
ES2364006T3 (en) 2011-08-22
JP2004522809A (en) 2004-07-29
EP1320386B1 (en) 2011-03-23
CA2420495C (en) 2010-03-09
US6696038B1 (en) 2004-02-24
US20030073619A1 (en) 2003-04-17
WO2002022174A1 (en) 2002-03-21
ATE502652T1 (en) 2011-04-15
WO2002022174A9 (en) 2003-04-03
EP1320386A1 (en) 2003-06-25
CA2420495A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
AU2001288598A1 (en) A novel cationic lipopolymer as biocompatible gene delivery agent
Lee et al. Self-assembled siRNA–PLGA conjugate micelles for gene silencing
Chae et al. Deoxycholic acid-conjugated chitosan oligosaccharide nanoparticles for efficient gene carrier
Van Bruggen et al. Nonviral gene delivery with cationic glycopolymers
O’Rorke et al. Non-viral polyplexes: Scaffold mediated delivery for gene therapy
AU2016288237B2 (en) Compositions and methods for delivery of gene editing tools using polymeric vesicles
Khan et al. Polysaccharide gene transfection agents
Nam et al. Target gene delivery from targeting ligand conjugated chitosan–PEI copolymer for cancer therapy
Casettari et al. Biomedical applications of amino acid-modified chitosans: a review
AU3468900A (en) Cyclodextrin polymers for use as drug carriers
Jeong et al. A new antisense oligonucleotide delivery system based on self-assembled ODN–PEG hybrid conjugate micelles
Fliervoet et al. Polymers and hydrogels for local nucleic acid delivery
ATE405251T1 (en) COMPOSITIONS FOR DELAYED RELEASE OF HYDROPHOBIC MEDICINAL PRODUCTS AND METHOD FOR THE PRODUCTION THEREOF
WO2004027045A3 (en) Polymer-linker-drug conjugates for targeted drug delivery
WO2017143061A1 (en) Compositions and methods for treatment of cystic fibrosis
WO2018044920A1 (en) Topical formulations based on ionic species for skin treatment
Fokina et al. Delivery of therapeutic RNA-cleaving oligodeoxyribonucleotides (deoxyribozymes): from cell culture studies to clinical trials
KR20220092760A (en) Composite particles using RNA expression cassettes having a structure capable of cell translation as an active ingredient and uses thereof
CA2523987A1 (en) Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
Bonengel et al. Zeta potential changing phosphorylated nanocomplexes for pDNA delivery
Lou et al. Poly (ethylene imine)‐g‐chitosan using EX‐810 as a spacer for nonviral gene delivery vectors
Rimann et al. Characterization of PLL-g-PEG-DNA nanoparticles for the delivery of therapeutic DNA
KR20220124057A (en) Multilayer Polyelectrolyte Nanoparticles Containing Active Ingredients, Uses Thereof, and Manufacturing Method Thereof
Liu et al. Nanobiomaterials in drug delivery: designing strategies and critical concepts for their potential clinical applications
Cho et al. Synthetic polynucleotides as endosomolytic agents and bioenergy sources